Abstract
Role of PD-L1 expression to guide immunotherapies in previously treated advanced NSCLC remains unclear and there is a lack of data comparing immune checkpoint inhibitors (ICIs) with each other. This network meta-analysis (NMA) aims to compare survival with ICIs to docetaxel and perform indirect comparisons between ICIs in the PD-L1 unselected population and by PD-L1 expression levels. PubMed was searched and study screening was performed by two independent reviewers. NMA of survival outcomes in the PD-L1 unselected population and by PD-L1 expression levels <1%, >=1%,>=5%,>=10%, and >=50% was performed. Head-to-head indirect comparisons were constructed and treatment rankings were provided. Potential survival benefits by PD-L1 expression level as compared to a PD-L1 unselected population were estimated. 5 trials with 3024 total patients were included for meta-analysis. Overall, ICIs improved survival across PD-L1 expression levels compared to docetaxel, although there was only weak evidence of benefit for individual ICI nivolumab or atezolizumab in PD-L1<1%. PD-L1 subgroups suggested positive dose-response relationship between PD-L1 expression levels with survival benefits. In addition, there were also survival benefits due to s...Continue Reading
Citations
Jul 11, 2018·International Journal of Cancer. Journal International Du Cancer·Yingcheng WuHuiqun Wu
Jan 31, 2019·Immunotherapy·Ni ZhangQian Chu
Nov 10, 2018·BMJ : British Medical Journal·Cheng XuJun Ma
Oct 22, 2019·International Journal of Cancer. Journal International Du Cancer·Xi LiuHao Hu
Sep 13, 2019·Shock·Eizo WatanabeShigeto Oda
Jul 9, 2020·Journal of Clinical Medicine·Jorge García-GonzálezLuis León-Mateos
Apr 27, 2019·Cancer Medicine·Ting SunYi Zhang
Nov 25, 2018·Journal for Immunotherapy of Cancer·Vivek VermaCharles R Thomas
Jan 18, 2019·JCO Clinical Cancer Informatics·Cédric M PanjePaul M Putora
May 23, 2018·Targeted Oncology·Hannah A Blair
Jun 27, 2019·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Taylor M WeisGregory P Kalemkerian
Apr 4, 2021·Journal of Clinical Medicine·Margarita MajemLuis Paz-Ares
Jul 31, 2021·Frontiers in Oncology·Xinqing LinChengzhi Zhou
Aug 27, 2021·PloS One·Keller J ToralEsther P Black
Nov 13, 2021·JAMA Network Open·Sreeram RamagopalanVivek Subbiah